ScholarIQanswers from OpenAlex & ORCID
Fred Yang
ResearcherPublications, citations & collaboration network
Fred Yang is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Fred Yang have?
ScholarIQindexed works
Fred Yang has 23 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Fred Yang have?
ScholarIQcitation count
Fred Yang has 1,049 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Fred Yang?
ScholarIQh-index
Fred Yang has an h-index of 10 in OpenAlex.
What is the i10-index of Fred Yang?
ScholarIQi10-index
Fred Yang has an i10-index of 10 in OpenAlex.
What is the OpenAlex record for Fred Yang?
ScholarIQopenalex
The OpenAlex for Fred Yang is on the source record.
What are the most-cited papers on Fred Yang?
ScholarIQmost cited works
Potential of Albiglutide, a Long-Acting GLP-1 Receptor Agonist, in Type 2 Diabetes
Julio Rosenstock, Jane E.B. Reusch, Mark Bush, Fred Yang, Murray Stewart, for the Albiglutide Study Group
HARMONY 3: 104-Week Randomized, Double-Blind, Placebo- and Active-Controlled Trial Assessing the Efficacy and Safety of Albiglutide Compared With Placebo, Sitagliptin, and Glimepiride in Patients With Type 2 Diabetes Taking Metformin
Bo Åhrén, Susan Johnson, Murray Stewart, Deborah T. Cirkel, Fred Yang, Caroline Perry, Mark N. Feinglos
Advancing Basal Insulin Replacement in Type 2 Diabetes Inadequately Controlled With Insulin Glargine Plus Oral Agents: A Comparison of Adding Albiglutide, a Weekly GLP-1 Receptor Agonist, Versus Thrice-Daily Prandial Insulin Lispro
Julio Rosenstock, Vivian Fonseca, Jorge Luiz Gross, Robert E. Ratner, Bo Åhrén, Francis C. C. Chow, Fred Yang, Diane Miller, Susan Johnson, Murray Stewart, Lawrence A. Leiter
Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise
Michael A. Nauck, Murray Stewart, Christopher Perkins, Angela R. Jones-Leone, Fred Yang, Caroline Perry, Rickey R. Reinhardt, Marc Rendell
Efficacy and Safety of the Once-Weekly GLP-1 Receptor Agonist Albiglutide Versus Sitagliptin in Patients With Type 2 Diabetes and Renal Impairment: A Randomized Phase III Study
Lawrence A. Leiter, Molly C. Carr, Murray Stewart, Angela R. Jones-Leone, Rhona Scott, Fred Yang, Yehuda Handelsman